The inaugural cohort of innovators has been selected to participate in UCLA Biodesign’s TechQuity Accelerator. The class of seven represents pre-seed through Series A-stage companies that are championing health equity-driven innovations across the life sciences, spanning the medical device, digital health, diagnostic, and biopharma sectors. The companies are developing solutions that address respiratory illness, chronic disease management, and healthcare accessibility for vulnerable populations.
The UCLA Health TechQuity Accelerator, provided in partnership with UCLA Health Biodesign and BioscienceLA, is uniquely focused on supporting teams that have innovative concepts and a firm commitment to improving long-term community health resilience. Launched in response to COVID-19’s disproportionate impact on vulnerable communities, the UCLA Health TechQuity Accelerator is designed to be sustainable beyond the pandemic, providing better health security by targeting four thematic areas: prevention, diagnosis, treatment, and community impact.